Transferrin secretion in medium of Müller glial cells from 8 to 12-day-old wild-type and transgenic mice decreases with the subcultures

A: Mouse transferrin (mTf) secretion in medium of cultured Müller glial (MG) cells from wild-type ( WT) and transgenic (Tg) mice at confluency after primary culture (P0) and at the first (P1) and the second passages (P2) was measured by radioimmunoassay (RIA; ng/ml). Each column represents the mean ±SEM. The asterisk represents statistical significance of differences between WT and Tg at P0, p<p><b>Copyright information:</b></p><p>Taken from "The protective role of transferrin in Müller glial cells after iron-induced toxicity"</p><p></p><p>Molecular Vision 2008;14():928-941.</p><p>Published online 20 May 2008</p><p>PMCID:PMC2391081.</p><p></p

Müller glial cells from transgenic mice are more resistant to iron-mediated stress than Müller glial cells from wild-type mice

A: Culture of Müller glial (MG) cells from wild-type (WT) and transgenic (Tg) mice at the first passage were treated with 100 µM of FeCl-NTA (FN), during 96 h. The number of cells was evaluated by counting in comparison to control condition. Each column represents the mean ±SEM. The triple asterisk represent statistical significance of differences between treated and control, respectively, for WT and Tg, and between control and treated, p<p><b>Copyright information:</b></p><p>Taken from "The protective role of transferrin in Müller glial cells after iron-induced toxicity"</p><p></p><p>Molecular Vision 2008;14():928-941.</p><p>Published online 20 May 2008</p><p>PMCID:PMC2391081.</p><p></p

Mouse transferrin and human transferrin proteins expression are modulated after iron stress

A: Mouse transferrin (mTf) secretion was measured by radioimmunoassay (RIA) in the culture medium of Müller glial (MG) cells from wild-type (WT) and transgenic (Tg) mice in control condition or after addition of 100 µM of FeCl-NTA (FN) during 96 h. Each column represents the mean ±SEM. The double asterisk represents statistical significance of differences between treated and control, respectively, for WT and Tg, p<p><b>Copyright information:</b></p><p>Taken from "The protective role of transferrin in Müller glial cells after iron-induced toxicity"</p><p></p><p>Molecular Vision 2008;14():928-941.</p><p>Published online 20 May 2008</p><p>PMCID:PMC2391081.</p><p></p

Changes in BMI over the course of treatment.

<p>Changes in BMI over the course of treatment.</p

Evolution of BMD.

<p>Changes in BMD at the lumbar spine in 18 RS patients from baseline to the end of treatment (after) and up to the last post-treatment visit (follow-up). Data are not shown for two patients who had spine arthrodesis preventing DXA at the vertebrae. Note that one patient has a normal BMD at start of therapy (z-score: -0.1); she had low BMD z-scores at the femoral necks (-2). The shaded area indicates the normal range.</p

Sites of the 37 fractures that occurred in the period preceding the bisphosphonate therapy.

<p>Sites of the 37 fractures that occurred in the period preceding the bisphosphonate therapy.</p

Characteristics of the 20 patients at the start of bisphosphonate therapy.

<p>Characteristics of the 20 patients at the start of bisphosphonate therapy.</p

Lower incidence of fracture after IV bisphosphonates in girls with Rett syndrome and severe bone fragility - Fig 4

<p><b>Changes in the biochemical markers of bone resorption over the course of treatment</b> (panel <b>A</b>: urinary calcium; panel <b>B</b>: deoxypyridinoline; panel <b>C</b>: Crosslaps).</p

Fractures before, during and after bisphosphonates.

<p>Number of fractures reported by the parents/guardians or diagnosed on vertebral X-rays before bisphosphonate therapy (grey and black bars), at the end of therapy (white bar) and at follow-up (no bar).</p